{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:56:15Z","timestamp":1791194175832,"version":"4.1.0"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The development and evaluation of anti-amyloid beta monoclonal antibodies (mAbs) for the treatment of Alzheimer\u2019s disease have been accompanied by extensive ethical debate spanning clinical trials, regulatory processes, prescribing practices, and healthcare delivery. This scoping review examined literature published between 2006 and 2026 to identify and clarify the landscape of ethical considerations surrounding the implementation, prescribing, and delivery of anti-amyloid mAbs across both research and clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Scopus, Web of Science, Embase, and Ovid EBM Reviews (including CENTRAL and CDSR) from 2006 to March 2026 using a structured search strategy. Eligible publications focused on ethical issues associated with the clinical translation of anti-amyloid mAbs. Two reviewers independently screened titles, abstracts, and full-text articles, with duplicate extraction performed on an initial subset of publications. The review was conducted using JBI guidance and reported according to PRISMA-ScR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 84 publications from 23 countries published between 2014 and 2026, including 12 original research studies, 1 systematic review, and 71 commentaries, narrative reviews, legal analyses, or practice guidelines. Analysis identified 32 subthemes, which were synthesized into 7 overarching themes: (1) beneficence and nonmaleficence, (2) respect for persons, (3) equity and accessibility, (4) evidence and trial integrity, (5) governance and stewardship, (6) relational and social impacts, and (7) health system readiness and sustainability. Among the 32 subthemes, uncertain clinical benefit and risk of harm (both within the beneficence and nonmaleficence theme) were discussed most frequently within the literature, each appearing in 61 publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The biomedical literature documents a broad range of ethical considerations relating to anti-amyloid mAbs. Despite this growing literature, it is primarily based on commentary, with few empirical studies, and even fewer incorporating the perspectives of patients, families, and clinicians. Doing so may add further context and nuance to ethical discussion about mAbs in the years ahead.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1953954","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:47:31Z","timestamp":1791193651000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ethical challenges in the clinical translation of anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: a scoping review"],"prefix":"10.3389","volume":"17","author":[{"given":"Alexandra","family":"Wicker","sequence":"first","affiliation":[{"name":"Biomedical Ethics Research Program, Mayo Clinic","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Courtright-Lim","sequence":"additional","affiliation":[{"name":"Biomedical Ethics Research Program, Mayo Clinic","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Tilburt","sequence":"additional","affiliation":[{"name":"Biomedical Ethics Research Program, Mayo Clinic","place":["Phoenix, AZ, United States"]},{"name":"Department of Internal Medicine, Mayo Clinic","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70235","article-title":"2025 Alzheimer's disease facts and figures","volume":"21","year":"2025","journal-title":"Alzheimers Dement"},{"key":"B2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.14336\/ad.2021.0529","article-title":"The cause of alzheimer's disease: The theory of multipathology convergence to chronic neuronal stress","volume":"13","author":"Decourt","year":"2022","journal-title":"Aging Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00664-z","article-title":"Passive anti-amyloid beta monoclonal antibodies: Lessons learned over past 20 years","volume":"13","author":"Wicker","year":"2024","journal-title":"Neurol Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12910-024-01141-w","article-title":"Ethical issues in genomics research in persons with alzheimer's disease\/alzheimer's disease-related dementia (AD\/ADRD): a systematic review","volume":"25","author":"Yakubu","year":"2024","journal-title":"BMC Med Ethics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12910-020-00572-5","article-title":"The full spectrum of ethical issues in dementia research: findings of a systematic qualitative review","volume":"22","author":"G\u00f6tzelmann","year":"2021","journal-title":"BMC Med Ethics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.112.116335","article-title":"The full spectrum of ethical issues in dementia care: systematic qualitative review","volume":"202","author":"Strech","year":"2013","journal-title":"Br J Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/alz.12444","article-title":"Aducanumab: Appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: Appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimer's Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0228-7","article-title":"Apolipoprotein E and alzheimer disease: pathobiology and targeting strategies","volume":"15","author":"Yamazaki","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.46","article-title":"Implications of emerging uses of genetic testing for alzheimer\u2019s disease","volume":"10","author":"Blasco","year":"2023","journal-title":"J Prev Alzheimer's Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1503","article-title":"Three FDA advisory panel members resign over approval of alzheimer\u2019s drug","volume":"373","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7326\/m18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Internal Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.11124\/jbies-22-00123","article-title":"Recommendations for the extraction, analysis, and presentation of results in scoping reviews","volume":"21","author":"Pollock","year":"2023","journal-title":"JBI Evidence Synthesis"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.46658\/JBIMES-24-01","volume-title":"JBI Manual for Evidence Synthesis","author":"Aromataris","year":"2024"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7324\/japs.2025.204843","article-title":"Lecanemab: The advent of biologicals in alzheimer's disease, affordability, and clinical relevance","volume":"15","author":"Anil","year":"2025","journal-title":"J Appl Pharm Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"111584","DOI":"10.1016\/j.jocn.2025.111584","article-title":"Time-saved and time-invested with anti-amyloid treatments in early alzheimer's disease: practical considerations","volume":"141","author":"Ara\u00fajo","year":"2025","journal-title":"J Clin Neurosci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3233\/jad-230040","article-title":"Playing russian roulette with alzheimer's disease patients: Do the cognitive benefits of lecanemab outweigh the risk of edema, stroke and encephalitis","volume":"92","author":"Atwood","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13195-016-0201-2","article-title":"Older patients are still under-represented in clinical trials of alzheimer's disease","volume":"8","author":"Banzi","year":"2016","journal-title":"Alzheimer's Res Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1590\/1980-5764-dn-2024-c002","article-title":"Use of anti-amyloid therapies for alzheimer's disease in brazil: a position paper from the scientific department of cognitive neurology and aging of the brazilian academy of neurology","volume":"18","author":"Barbosa","year":"2024","journal-title":"Dement Neuropsychol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70258","article-title":"Current advances and unmet needs in alzheimer's disease trials for individuals with down syndrome: Navigating new therapeutic frontiers","volume":"21","author":"Barroeta","year":"2025","journal-title":"Alzheimers Dement"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9343514","article-title":"Aducanumab therapy to treat alzheimer's disease: A narrative review","volume":"2022","author":"Beshir","year":"2022","journal-title":"Int J Alzheimer's Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/14728214.2024.2304059","article-title":"How promising are the latest monoclonal antibodies targeting amyloid-\u03b2 for the treatment of early alzheimer's disease","volume":"29","author":"Beveridge","year":"2024","journal-title":"Expert Opin Emerg Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5694\/mja2.52359","article-title":"Contextualising the benefits and risks of anti-amyloid therapy for patients with alzheimer disease and their care team","volume":"221","author":"Bhalala","year":"2024","journal-title":"Med J Aust"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.37","article-title":"Anti-amyloid therapies for alzheimer's disease: An alzheimer europe position paper and call to action","volume":"11","author":"Bradshaw","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207505","article-title":"Lecanemab: Looking before we leap","volume":"101","author":"Burke","year":"2023","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/amajethics.2023.777","article-title":"What might aducanumab teach us about clinicians' judgment about whether to recommend emerging alzheimer's interventions","volume":"25","author":"Burroughs","year":"2023","journal-title":"AMA J Ethics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2026.01.267","article-title":"Simulated shared and supported decision making for amyloid immunotherapy in alzheimer's disease: A bicentric study","volume":"182","author":"Burry","year":"2026","journal-title":"Rev Neurol (Paris)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71230","article-title":"Clinical meaningfulness of anti-amyloid therapies in early alzheimer's disease: Perspectives from the east and southeast asia region","volume":"22","author":"Chen","year":"2026","journal-title":"Alzheimers Dement"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18652","article-title":"Monoclonal anti-amyloid antibodies for the treatment of alzheimer's disease and the hesitant geriatrician","volume":"72","author":"Chin","year":"2024","journal-title":"J Am Geriatr Soc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000013053","article-title":"Decisions with patients and families regarding aducanumab in alzheimer disease, with recommendations for consent: AAN position statement","volume":"98","author":"Chiong","year":"2022","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early alzheimer's disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J Prev Alzheimer's Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad094","article-title":"Lecanemab: turning point, or status quo? An ethics perspective","volume":"146","author":"Daly","year":"2023","journal-title":"Brain"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2024.108314","article-title":"Measuring our language about anti-amyloid antibodies in alzheimer's disease: Technical, theoretical, and lay language considerations","volume":"241","author":"Daly","year":"2024","journal-title":"Clin Neurol Neurosurg"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jradnu.2024.04.004","article-title":"Ethical issues around treatment-induced amyloid-related imaging abnormalities in alzheimer's disease","volume":"43","author":"Daly","year":"2024","journal-title":"J Radiol Nurs"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/198674","article-title":"Anti-amyloid treatments in alzheimer's disease: elegance, evidence and ethics","volume":"33","author":"Daly","year":"2024","journal-title":"Adv Clin Exp Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100260","article-title":"Treatments for alzheimer\u2019s and the declaration of helsinki","volume":"12","author":"Daly","year":"2025","journal-title":"J Prev Alzheimer's Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70309","article-title":"Genetically determined alzheimer's disease research advances: The down syndrome & autosomal dominant alzheimer's disease 2024 conference","volume":"21","author":"Falg\u00e0s","year":"2025","journal-title":"Alzheimers Dement"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2026.101609","article-title":"Anti-amyloid therapies and the transformation of alzheimer's care pathways: early lessons from the frontline","volume":"64","author":"Filippi","year":"2026","journal-title":"Lancet Reg Health Eur"},{"key":"B42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/hast.1264","article-title":"Alzheimer's and aducanumab: Unjust profits and false hopes","volume":"51","author":"Fleck","year":"2021","journal-title":"Hastings Cent Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01389-3","article-title":"Alzheimer's disease outlook: controversies and future directions","volume":"406","author":"Frisoni","year":"2025","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2307\/45227780","article-title":"A black alzheimer's patient wants to be part of the cure","volume":"36","author":"Gray","year":"2017","journal-title":"Health Aff (Millwood)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-023-00750-x","article-title":"Clinical management in alzheimer's disease in the era of disease-modifying therapies","volume":"25","author":"Guo","year":"2023","journal-title":"Curr Treat Options Neurol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s41983-023-00684-w","article-title":"Aducanumab: an uprising hope with vague horizons","volume":"59","author":"Hazegh Fetratjoo","year":"2023","journal-title":"Egyptian J Neurology Psychiatry Neurosurg"},{"key":"B47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-med-051022-043645","article-title":"Lessons learned from approval of aducanumab for alzheimer's disease","volume":"75","author":"Heidebrink","year":"2024","journal-title":"Annu Rev Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102348","article-title":"Donanemab, another anti-alzheimer's drug with risk and uncertain benefit","volume":"99","author":"H\u00f8ilund-Carlsen","year":"2024","journal-title":"Ageing Res Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17462","article-title":"Instead of wasting money on aducanumab, pay for programs proven to help people living with dementia","volume":"69","author":"Hunt","year":"2021","journal-title":"J Am Geriatrics Soc"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2025.40.e215","article-title":"Practical guide of the korean association for geriatric psychiatry to anti-amyloid monoclonal antibody therapy for alzheimer's disease: Focused on lecanemab","volume":"40","author":"Jeon","year":"2025","journal-title":"J Korean Med Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3123","article-title":"Aducanumab and the business of Alzheimer disease-some choice","volume":"78","author":"Karlawish","year":"2021","journal-title":"JAMA Neurol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14204","article-title":"Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent","volume":"21","author":"Karneboge","year":"2025","journal-title":"Alzheimers Dement"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00869-w","article-title":"Care partners' perceptions of amyloid-targeting therapy and treat-to-clearance for Alzheimer's disease in Japan: A qualitative study","volume":"15","author":"Katayama","year":"2026","journal-title":"Neurol Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3233\/jad-230099","article-title":"The anti-amyloid monoclonal antibody lecanemab: 16 cautionary notes","volume":"94","author":"Kepp","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/gps.3958","article-title":"Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment","volume":"29","author":"Lawrence","year":"2014","journal-title":"Int J Geriatr Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/jad-240684","article-title":"A framework for best practices and readiness in the advent of anti-amyloid therapy for early Alzheimer's disease in Asia","volume":"101","author":"Lee","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-024-02465-8","article-title":"Monoclonal anti-amyloid antibody treatment: The epidemiological profile of the target patients in Austria and the status of treatment-eligible patients registered at an outpatient memory clinic","volume":"137","author":"Lee","year":"2025","journal-title":"Wien Klin Wochenschr"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q2010","article-title":"Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer's drug","volume":"386","author":"Lenzer","year":"2024","journal-title":"Bmj"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.31913","article-title":"Valuing Alzheimer disease therapies-considering costs and benefits beyond the patient","volume":"4","author":"Lin","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18815","article-title":"Hope is the thing with feathers","volume":"72","author":"Lundebjerg","year":"2024","journal-title":"J Am Geriatrics Soc"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17523","article-title":"Of education and public policy: Aducanumab","volume":"70","author":"Lundebjerg","year":"2022","journal-title":"J Am Geriatrics Soc"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1177\/13872877241301806","article-title":"The importance of non-pharmacological interventions to improve cognitive reserve prior to the administration of a drug against the causative agent of Alzheimer's disease","volume":"103","author":"Maki","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11704","article-title":"Donanemab for Alzheimer disease-who benefits and who is harmed","volume":"330","author":"Manly","year":"2023","journal-title":"Jama"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.01.009","article-title":"Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit","volume":"12","author":"Molinuevo","year":"2016","journal-title":"Alzheimers Dement"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2024.11.011","article-title":"Do caregivers value the new antiamyloid treatments for Alzheimer's disease more than home-based care","volume":"33","author":"Morehouse","year":"2025","journal-title":"Am J Geriatr Psychiatry"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3233\/adr-220023","article-title":"Under-represented populations left out of Alzheimer's disease treatment with aducanumab: Commentary on ethics","volume":"6","author":"Padala","year":"2022","journal-title":"J Alzheimers Dis Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/alz70858_096332","article-title":"Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers","volume":"11","author":"Parks","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1177\/13872877251329519","article-title":"A qualitative study of people with Alzheimer's disease in a memory clinic considering lecanemab treatment","volume":"105","author":"Parks","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/nejmp2111320","article-title":"Controversy and progress in Alzheimer's disease - FDA approval of aducanumab","volume":"385","author":"Rabinovici","year":"2021","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000207757","article-title":"Antiamyloid monoclonal antibody therapy for Alzheimer disease: Emerging issues in neurology","volume":"101","author":"Ramanan","year":"2023","journal-title":"Neurology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14199","article-title":"Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement","volume":"20","author":"Rentz","year":"2024","journal-title":"Alzheimers Dement"},{"key":"B72","doi-asserted-by":"publisher","first-page":"183","DOI":"10.30773\/pi.2025.0400","article-title":"Evolving Alzheimer's disease clinical practice: Updated diagnostic criteria, fluid biomarkers, and special considerations for anti-amyloid therapies","volume":"23","author":"Roh","year":"2026","journal-title":"Psychiatry Investig"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1212\/con.0000000000001164","article-title":"The medicolegal and ethical dimensions of physician prescription reluctance","volume":"28","author":"Rose","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41419-026-08456-z","article-title":"Should all MCI with Alzheimer's biological diagnosis receive anti-amyloid therapy","volume":"17","author":"Rossini","year":"2026","journal-title":"Cell Death Dis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.70054","article-title":"An analysis of institutional anti-amyloid websites","volume":"73","author":"Rydberg","year":"2025","journal-title":"J Am Geriatrics Soc"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2284305","article-title":"Advances in amyloid-targeting monoclonal antibodies for Alzheimer's disease: Clinical and public health issues","volume":"23","author":"Salemme","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1159\/000545800","article-title":"Anti-amyloid treatments: A therapeutic revolution, ready for Europe","volume":"25","author":"Salvioni Chiabotti","year":"2025","journal-title":"Neurodegener Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.7326\/m23-3377","article-title":"Talking with patients about the new anti-amyloid Alzheimer disease medications","volume":"177","author":"Sarkisian","year":"2024","journal-title":"Ann Internal Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70652","article-title":"Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriers","volume":"21","author":"Sato","year":"2025","journal-title":"Alzheimer's Dementia"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/alz70861_108615","article-title":"Anti-amyloid treatments: Why we think they are worth it","volume":"21","author":"Schindler","year":"2025","journal-title":"Alzheimer's Dementia Conference: Alzheimer's Assoc Int Conference AAIC"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.37","article-title":"Aducanumab trials EMERGE but don\u2019t ENGAGE","volume":"9","author":"Schneider","year":"2022","journal-title":"J Prev Alzheimer's Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0045-1807718","article-title":"Amyloid immunotherapy for Alzheimer's disease: The case for cautious adoption","volume":"83","author":"Schott","year":"2025","journal-title":"Arq Neuropsiquiatr"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.71","article-title":"Balancing the conflicting goals for treatment of Alzheimer\u2019s disease with monoclonal antibodies","volume":"10","author":"Scrase","year":"2023","journal-title":"J Prev Alzheimer's Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2025.00314","article-title":"Uninformed consent in an Alzheimer\u2019s clinical trial","volume":"44","author":"Shields","year":"2025","journal-title":"Health Affairs"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100068","article-title":"Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research","volume":"12","author":"Smith","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2131","article-title":"Unfairness to patients with Alzheimer disease in Medicare's coverage of antiamyloid immunotherapy","volume":"79","author":"Stern","year":"2022","journal-title":"JAMA Neurol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2024-12-2","article-title":"Lecanemab for mild Alzheimer disease - is there a way forward","volume":"14","author":"Tampi","year":"2025","journal-title":"Drugs Context"},{"key":"B88","doi-asserted-by":"publisher","first-page":"77","DOI":"10.17712\/nsj.2023.2.20220133","article-title":"The future of Alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology","volume":"28","author":"Tayeb","year":"2023","journal-title":"Neurosci (Riyadh)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13795","article-title":"Ethical considerations for the use of anti-amyloid immunotherapy in patients with early Alzheimer's disease","volume":"20","author":"van Veluw","year":"2024","journal-title":"Alzheimers Dement"},{"key":"B90","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.neurol.2022.08.002","article-title":"High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: Putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France","volume":"178","author":"Villain","year":"2022","journal-title":"Rev Neurol (Paris)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1080\/08959420.2023.2238534","article-title":"Analysis of the first round of public comments for the national coverage determination for monoclonal antibodies in the treatment of Alzheimer's disease","volume":"36","author":"Wahl","year":"2024","journal-title":"J Aging Soc Policy"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13759","article-title":"People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare","volume":"295","author":"Wahlberg","year":"2024","journal-title":"J Intern Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1682","article-title":"Aducanumab for Alzheimer's disease","volume":"374","author":"Walsh","year":"2021","journal-title":"Bmj"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14108","article-title":"Considering challenges for the new Alzheimer's drugs: Clinical, population, and health system perspectives","volume":"20","author":"Walsh","year":"2024","journal-title":"Alzheimer's Dementia"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2025.02.007","article-title":"Developing treatment models for the delivery of the antiamyloid therapy, lecanemab: Considerations for implementation of lecanemab in healthcare systems","volume":"33","author":"Weber","year":"2025","journal-title":"Am J Geriatric Psychiatry"},{"key":"B96","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3233\/jad-220264","article-title":"Making the case for the accelerated withdrawal of aducanumab","volume":"87","author":"Whitehouse","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01405-0","article-title":"Anti-amyloid immunotherapies for Alzheimer's disease: A 2023 clinical update","volume":"20","author":"Yadollahikhales","year":"2023","journal-title":"Neurotherapeutics"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s11948-022-00422-0","article-title":"A review of scientific ethics issues associated with the recently approved drugs for Alzheimer's disease","volume":"29","author":"Yeo-Teh","year":"2023","journal-title":"Sci Eng Ethics"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afae023","article-title":"Monoclonal antibodies for treating early Alzheimer disease-a commentary on recent 'positive' trials","volume":"53","author":"Scott","year":"2024","journal-title":"Age Ageing"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.5124\/jkma.25.0052","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"B101","first-page":"1","article-title":"Care ethics","volume-title":"Encyclopedia of Global Justice","author":"McLaren","year":"2025"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1953954\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:47:33Z","timestamp":1791193653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1953954\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":101,"alternative-id":["10.3389\/fpsyt.2026.1953954"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1953954","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1953954"}}